Beleodaq Earns FDA Approval for Peripheral T-cell Lymphoma

Share this content:
Beleodaq Earns FDA Approval for Peripheral T-cell Lymphoma
Beleodaq Earns FDA Approval for Peripheral T-cell Lymphoma

The FDA announced the approval of Beleodaq (belinostat; Spectrum Pharmaceuticals) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Beleodaq is a pan HDAC inhibitor that works by stopping enzymes that contribute to T-cells becoming cancerous.

RELATED: Lymphoma Resource Center

The safety and effectiveness of Beleodaq was evaluated in a clinical study involving 129 participants with relapsed or refractory PTCL. All participants were treated with Beleodaq until their disease progressed or side effects became unacceptable. Results demonstrated that 25.8% of participants had a complete response or partial response after treatment.

For more information call (877) 387-4538 or visit

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs